Computational & In-Silico Drug Discovery CROs in Asia-Pacific
9 published
9 published CROs match Computational & In-Silico Drug Discovery in Asia-Pacific.
Locations in this set include United States, China, India, United Kingdom, Italy, and Japan.
Capabilities that show up most often in this set: Small Molecule, Oligonucleotide, Peptide, Antibody-Drug Conjugate (ADC), and Biologics (Other).
Matching companies
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
Aurigene Pharmaceutical Services LimitedIntegrated CRO-CDMO with 25+ years of discovery and development expertise across small and large molecules, operating 16 US FDA-inspected cGMP facilities across three manufacturing countries.
ChemDivChemDiv is a fully integrated target-to-clinic CRO headquartered in San Diego, CA, offering drug discovery services including medicinal chemistry, CADD, ADME/DMPK, toxicology, and custom synthesis alongside the industry's largest commercial screening library of 1.6M compounds.
ChemPartnerGlobal preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
HitGen Inc.HitGen Inc. provides drug discovery services built on DNA-encoded library (DEL), fragment-based (FBDD/SBDD) and computational platforms for pharmaceutical and biotech clients. The company also offers oligonucleotide CDMO services and reports serving more than 600 clients globally.
PI Health SciencesPI Health Sciences is an integrated CRDMO offering end-to-end drug discovery, development, and manufacturing services with R&D and manufacturing locations in Europe and India.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /services/computational-drug-discovery/apac.md